Daxor Co. (NYSEAMERICAN:DXR) saw a large decline in short interest during the month of March. As of March 29th, there was short interest totalling 168,087 shares, a decline of 23.7% from the March 15th total of 220,337 shares. Based on an average trading volume of 48,426 shares, the short-interest ratio is presently 3.5 days. Approximately 21.5% of the company’s shares are sold short.
An institutional investor recently bought a new position in Daxor stock. Shine Investment Advisory Services Inc. bought a new position in Daxor Co. (NYSEAMERICAN:DXR) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 45,454 shares of the company’s stock, valued at approximately $512,000. Shine Investment Advisory Services Inc. owned 1.22% of Daxor at the end of the most recent quarter.
Shares of DXR traded down $0.15 during trading hours on Friday, reaching $9.35. The stock had a trading volume of 30,017 shares, compared to its average volume of 47,778. Daxor has a 52 week low of $4.30 and a 52 week high of $19.95.
WARNING: This piece was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/daxor-co-dxr-short-interest-down-23-7-in-march.html.
Daxor Company Profile
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.